Fig. 2From: Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA reviewAducanumab-related biomarker changes are associated with slowing in clinical decline (Study 302). Correlations between biomarkers and clinical outcomes. All associations are partial Spearman correlation of change from baseline to week 78 between each variableBack to article page